DK2771022T3 - Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf - Google Patents

Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2771022T3
DK2771022T3 DK12840074.4T DK12840074T DK2771022T3 DK 2771022 T3 DK2771022 T3 DK 2771022T3 DK 12840074 T DK12840074 T DK 12840074T DK 2771022 T3 DK2771022 T3 DK 2771022T3
Authority
DK
Denmark
Prior art keywords
skelets
derivated
cd40l
scaffolds
methods
Prior art date
Application number
DK12840074.4T
Other languages
Danish (da)
English (en)
Inventor
Anthony Coyle
Manuel Baca
Thomas Thisted
Stacey Drabic
Luba Grinberg
Shabazz Novarra
Vaheh Oganesyan
Ronald Herbst
David Kenneth Spencer
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Application granted granted Critical
Publication of DK2771022T3 publication Critical patent/DK2771022T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/80—Data visualisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Computing Systems (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
DK12840074.4T 2011-10-11 2012-10-10 Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf DK2771022T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161546028P 2011-10-11 2011-10-11
PCT/US2012/059477 WO2013055745A2 (en) 2011-10-11 2012-10-10 Cd40l-specific tn3-derived scaffolds and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2771022T3 true DK2771022T3 (da) 2020-09-28

Family

ID=48082729

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12840074.4T DK2771022T3 (da) 2011-10-11 2012-10-10 Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf

Country Status (22)

Country Link
US (5) US10000553B2 (enExample)
EP (2) EP2771022B1 (enExample)
JP (5) JP6140712B2 (enExample)
KR (4) KR102434073B1 (enExample)
CN (3) CN103874501B (enExample)
AU (1) AU2012323316B2 (enExample)
BR (1) BR112014008804A2 (enExample)
CA (1) CA2851667A1 (enExample)
CY (1) CY1123690T1 (enExample)
DK (1) DK2771022T3 (enExample)
ES (1) ES2819075T3 (enExample)
HR (1) HRP20201513T1 (enExample)
HU (1) HUE051439T2 (enExample)
LT (1) LT2771022T (enExample)
MX (2) MX367013B (enExample)
PT (1) PT2771022T (enExample)
RS (1) RS60828B1 (enExample)
RU (1) RU2704992C2 (enExample)
SG (2) SG11201400567QA (enExample)
SI (1) SI2771022T1 (enExample)
SM (1) SMT202000513T1 (enExample)
WO (1) WO2013055745A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059298A2 (en) * 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
KR102434073B1 (ko) 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
CA3052084A1 (en) * 2017-01-09 2018-07-12 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
US11905313B2 (en) * 2017-11-28 2024-02-20 The United States of America, as represented by the Secretary, Department of Health and Human Services. Recombinant RSV G proteins and their use
WO2020068723A1 (en) * 2018-09-24 2020-04-02 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd154 antibody
KR102919125B1 (ko) * 2018-09-26 2026-01-27 비엘라 바이오, 인크. Cd40l 길항제 및 이의 용도
US12247320B2 (en) 2018-10-24 2025-03-11 Brandeis University Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family PGT128
US11447551B2 (en) 2018-12-28 2022-09-20 Sparx Bioscience Limited Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
CN111440253B (zh) * 2019-01-17 2021-08-27 中国科学院上海药物研究所 立方形环糊精骨架-rgd组合物及其制备方法
CA3219742A1 (en) * 2021-05-21 2022-11-24 Gabor Illei Cd40l antagonist and uses thereof in the treatment of lupus nephritis
MX2024003985A (es) * 2021-09-28 2024-04-29 Viela Bio Inc Andamios derivados de tn3 especificos para cd40l para su uso en el tratamiento y prevencion de la artritis reumatoide.
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
EP4703385A1 (en) 2023-04-28 2026-03-04 Fortvita Biologics Inc. Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
EP0781297A4 (en) 1994-09-16 1999-05-19 Scripps Research Inst CYTOTACTIN DERIVATIVES THAT PROMOTE NEURONAL CONNECTIONS AND NEURITE GROWTH AND PROCESS YOUR PRODUCTION AND APPLICATION
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
US6160089A (en) 1998-07-08 2000-12-12 Mitsui Chemicals, Inc. Method for secretory production of human growth hormone
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
CA2350417C (en) 1998-12-02 2010-02-09 Bristol-Myers Squibb Company Dna-protein fusions and uses thereof
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2377468C (en) 1999-07-27 2010-04-20 Phylos, Inc. Peptide acceptor ligation methods
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2003000856A2 (en) 2001-06-21 2003-01-03 Phylos, Inc. In vitro protein interaction detection systems
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
DK2339016T3 (da) 2002-03-29 2017-01-23 Danisco Us Inc Øget produktion af subtilisiner
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
WO2004001009A2 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
KR100524872B1 (ko) 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
KR100852415B1 (ko) 2004-07-13 2008-08-18 재단법인서울대학교산학협력재단 인간 테나신―ｃ 유래의 신규한 헤파린-결합부위를포함하는 폴리펩타이드 및 그의 유도체
GB0416651D0 (en) 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
WO2007053661A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
JP4959226B2 (ja) 2006-05-19 2012-06-20 独立行政法人産業技術総合研究所 スリーフィンガー様蛋白質ライブラリ
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
JP5518702B2 (ja) 2007-07-03 2014-06-11 ダヌタ・クルセフスカ α−ケトグルタレートの新規の医学的用途
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
EP2215246B1 (en) * 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
AU2008345424A1 (en) * 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
CN102076713B (zh) 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
AU2009303526B2 (en) * 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
CN102549012B (zh) 2009-05-07 2015-07-01 诺维信生物制药丹麦公司 纯化白蛋白的方法
WO2011020033A2 (en) 2009-08-13 2011-02-17 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
WO2011051466A1 (en) * 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
KR20130056870A (ko) 2010-04-13 2013-05-30 메디뮨 엘엘씨 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드
AU2011325134B2 (en) 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
JP2014177354A (ja) 2011-07-05 2014-09-25 Asahi Glass Co Ltd 窓ガラス
KR102434073B1 (ko) 2011-10-11 2022-08-18 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
AU2015263285A1 (en) 2014-05-19 2016-11-24 Medimmune Limited Treatment for rheumatoid arthritis
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
KR102919125B1 (ko) 2018-09-26 2026-01-27 비엘라 바이오, 인크. Cd40l 길항제 및 이의 용도

Also Published As

Publication number Publication date
PT2771022T (pt) 2020-09-14
US20250257120A1 (en) 2025-08-14
RS60828B1 (sr) 2020-10-30
JP7068231B2 (ja) 2022-05-16
CN108948196B (zh) 2022-09-23
KR102132997B1 (ko) 2020-07-14
KR20240142616A (ko) 2024-09-30
EP2771022A2 (en) 2014-09-03
JP2025000710A (ja) 2025-01-07
CN103874501B (zh) 2018-07-20
KR20140077199A (ko) 2014-06-23
SG10201707813YA (en) 2017-11-29
ES2819075T3 (es) 2021-04-14
JP2015501147A (ja) 2015-01-15
CN116063509A (zh) 2023-05-05
LT2771022T (lt) 2020-12-10
JP2017195884A (ja) 2017-11-02
AU2012323316B2 (en) 2017-08-10
JP2019205433A (ja) 2019-12-05
SMT202000513T1 (it) 2020-11-10
US11555062B2 (en) 2023-01-17
CN108948196A (zh) 2018-12-07
CY1123690T1 (el) 2022-03-24
KR20220116585A (ko) 2022-08-23
US20180312572A1 (en) 2018-11-01
BR112014008804A2 (pt) 2017-06-13
US20220089688A1 (en) 2022-03-24
SI2771022T1 (sl) 2020-12-31
JP6140712B2 (ja) 2017-05-31
US20230242619A1 (en) 2023-08-03
RU2704992C2 (ru) 2019-11-01
EP2771022B1 (en) 2020-07-01
MX367013B (es) 2019-08-02
RU2014117511A (ru) 2015-11-20
MX2019009104A (es) 2019-09-10
SG11201400567QA (en) 2014-05-29
KR20200085376A (ko) 2020-07-14
JP6539300B2 (ja) 2019-07-03
US11104720B2 (en) 2021-08-31
JP7560507B2 (ja) 2024-10-02
WO2013055745A2 (en) 2013-04-18
CN103874501A (zh) 2014-06-18
US10000553B2 (en) 2018-06-19
JP2022115916A (ja) 2022-08-09
HRP20201513T1 (hr) 2020-12-11
US20150098955A1 (en) 2015-04-09
RU2019133467A (ru) 2020-07-06
EP3753567A1 (en) 2020-12-23
CA2851667A1 (en) 2013-04-18
AU2012323316A1 (en) 2014-03-20
HUE051439T2 (hu) 2021-03-01
KR102434073B1 (ko) 2022-08-18
EP2771022A4 (en) 2015-08-05
HK1201463A1 (en) 2015-09-04
MX2014004065A (es) 2014-08-22
WO2013055745A3 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
DK3290528T3 (da) Fremgangsmåder og sammensætninger til nukleinsyresekventering
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3725807T3 (da) Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
DK2764459T3 (da) Fremgangsmåder og processer til ikke-invasiv bedømmelse af genetiske variationer
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK3603693T3 (da) Filter og rammeapparat og fremgangsmåde til anvendelse
DK2840593T3 (da) Forbedret afbryderindretning og fremgangsmåde til fremstilling dertil
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2730878T3 (da) Pladestak og fremgangsmåde til fremstilling af en pladestak
DK2914575T3 (da) Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
DK2815066T3 (da) Selektivt korroderbart borehulsartikel og fremgangsmåde til anvendelse
DK2520792T3 (da) Hejsesystem og fremgangsmåde til tilvejebringelse af et hejsesystem
DK2663864T3 (da) Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne
DK2768321T3 (da) Fremgangsmåder og sammensætninger til induktion af mæthed
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK2622532T3 (da) Fremgangsmåde til kollaborativ beregning
DK2727647T3 (da) Kemisk reaktionsapparat og kemisk reaktionsmetode
DK2974732T3 (da) Olie-ekstraheret produkt af indigo naturalis og fremgangsmåde til fremstilling og anvendelse deraf